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Abstract
 .  .A new monoclonal antibody against malondialdehyde MDA -treated low density lipoprotein LDL was raised using
homogenate of human atheroma as immunogen. This antibody, DLH2, was obtained by selecting the clones which did not
 .react to native LDL but did react to copper-induced oxidized LDL OxLDL . DLH2 showed a greater reactivity to
MDA-LDL than to OxLDL. When LDL was treated with various aldehyde containing reagents, treatment of LDL with
glutaraldehyde or MDA greatly increased the reactivity to the antibody, while LDL treated with 2,4-hexadienal or
4-hydroxynonenal was not reactive. Among many proteins tested, high density lipoprotein, bovine serum albumin and
hemoglobin showed significant reactivity to DLH2 after they were treated with MDA or glutaraldehyde. When low density
and high density lipoproteins treated with MDA were subjected to immunoblot analysis, newly formed products larger than
the original apolipoproteins were detected with the antibody, suggesting that this antibody recognizes aggregated proteins
with divalent short chain cross linkers. The antigenic materials were shown by immunohistochemical analysis to be present
in foamy macrophages in human atheromatous lesions. DLH2 antigen did not colocalize either with apolipoprotein B.
Furthermore, we found a massive accumulation of the antigenic material in Kupffer cells in the liver of rats treated with
alcohol and carbonyl iron, a model of hepatic fibrosis due to oxidative stress. These results suggest the presence of cross
linked proteins in damaged tissues. q 1998 Elsevier Science B.V.
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1. Introduction
Lipid peroxidation has been thought to be involved
in a number of diseases and pathological conditions
w x1,2 . A number of studies have shown increased
levels of lipid peroxidation products in lesions and
sera in a variety of pathological conditions including
w xatherosclerosis and alcoholic liver disease 2–8 . Lipid
peroxidation products containing aldehyde group,
 .such as malondialdehyde MDA and 4-hydroxynon-
 . w xenal HNE are known to react to proteins 9–11 .
Modification of proteins could be an important factor
in the pathogenesis of various diseases through inac-
tivation of enzymes and deformation of structural
proteins. For example, accumulation of MDA-mod-
ified collagens was demonstrated in nephrotic
w xglomeruli 12 .
It is well known that long term intake of alcohol
leads to hepatic cell damage and finally to liver
cirrhosis. Hepatic fibrogenesis is a complicated pro-
cess, which has not been fully clarified yet, but
induction of cytochrome P-450 and lipid peroxida-
w xtion appeared to be involved in 5,13 .
Oxidative modification of low density lipoprotein
 .LDL has been extensively studied, since it is thought
to be involved in early development of athero-
w xsclerosis 2,10 . Modified LDL such as MDA-treated
 .LDL MDA-LDL was shown to be taken up by
macrophages through scavenger receptors to form
w xfoam cells 9,10,14,15 , which are typical features
w xobserved in atherosclerotic lesions 16 . Presence of
anti-MDA-LDL autoantibodies in patients of cardio-
vascular diseases also suggested the pathological im-
w xplication of MDA-LDL 17 .
Several investigators have suggested the presence
of MDA-LDL-like products in atherosclerotic aortas
w x w xof rabbits 18,19 and other tissues 5,10 using mon-
oclonal antibodies against MDA-lysine adducts.
MDA-LDL should be one good model of OxLDL
which is a mixture of heterogenously modified
lipoprotein particles. However, little has been studied
on the structural changes of these modified LDLs as
well as correlation between MDA-LDL and OxLDL
 .in vivo. Monoclonal antibodies mAbs against cer-
tain modified proteins is a useful tool for characteriz-
ing their structures and metabolism in vivo. We have
obtained a series of mAbs which react with copper-
induced OxLDL, using homogenate of human
w xatheroma as immunogen 20 . One of these mAbs,
DLH3, was shown to recognize oxidized phos-
w xphatidylcholines containing aldehyde groups 21 . In
the present study we focused on another mAb in the
series which reacted strongly with cross linked pro-
teins. We found the presence of cross linked proteins
in damaged tissues especially in foam cells in human
atheroma, and in Kupffer cells in pre-fibrotic rat
liver.
2. Materials and methods
2.1. Preparation and modification of lipoproteins
LDL and other lipoproteins were separated from
human plasma by sodium bromide stepwise density
w xgradient centrifugation 22 . All sodium bromide stock
solutions contained 0.25 mM EDTA. The fractions
with a density of 1.019–1.063 grcm3 and 1.063–1.15
grcm3 were pooled as LDL and high density
 .lipoprotein HDL , respectively. MDA-LDL was pre-
w xpared by the method of Fogelman et al. 13 . To 1 ml
 .of LDL solution 0.5 mgrml in 50 mM phosphate
buffer, pH 6.5, was added 5ml of 1 M MDA reagent
  .prepared from malondialdehyde bis dimethyl acetal
 .Aldrich, Milwaukee, WI by acidic hydrolysis just
.before use , and the mixture was incubated for 3 h at
378C. The reaction was stopped by extensive dialysis
of the reaction mixture against phosphate-buffered
 .saline PBS containing 0.25 mM EDTA at 48C.
 .Modification of LDL with glutaraldehyde GA , 2,4-
hexadienal, and HNE a kind gift from Dr. Esterbauer
.of University of Graz, Austria were carried out using
the same procedure as for MDA-LDL. Modification
of other proteins with MDA and GA was also carried
out using the same method as for MDA-LDL. Prior
to oxidation, LDL was passed through a 10DG desalt-
 .ing column Bio-Rad, Richmond, VA, USA to re-
 .move the EDTA and the LDL 0.2 mgrml was
oxidized by incubation with 5 mM CuSO at 378C for4
3 h. The OxLDL prepared under the condition showed
 .an increase in relative mobility 1.8q0.2 on agarose
electrophoresis and production of 56.7q9.7 nmol of
 .thiobarbituric acid reactive substances TBARS per
mg protein. The reaction was stopped by addition of
 .EDTA final concentration 0.25 mM . Glycated LDL
was prepared according to the procedure of Bucala et
w xal. 23 .
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 .Fig. 1. The reactivity of mAbs DLH2 to modified LDLs. A
1mg each of native LDL and various modified LDL were coated
as antigen onto microtiter wells. The ELISA was carried out with
 .DLH2 1:2000 dilution, closed bar as described under the Sec-
tion 2. Values indicated are mean"standard deviation of three
 .different experiments. B The free amino group was determined
using a fluorescent dye fluorescamine. The values represent
relative amino group concentrations of modified LDL prepara-
tions against the original native LDL.
2.2. Preparation of mAb
The anti-OxLDL mAb DLH2 was prepared as
w xdescribed previously 20 . Briefly, female BALBrc
 .Fig. 2. The reactivity of DLH2 to MDA-modified proteins. A
Various proteins were treated with 10 mM MDA. 1mg of MDA-
 .  .treated closed bar and untreated hatched bar samples were
coated as antigen onto the microtiter wells. The ELISA was
 .carried out with DLH2 1:2000 dilution . Values indicated are
 .mean"standard deviation of three different experiments. B The
free amino group was determined using a fluorescent dye fluo-
rescamine. The values represent relative amino group concentra-
tions of modified LDL preparations against the original native
LDL. Hb; bovine hemoglobin.
mice were immunized three times with homogenates
of human atheromatous plaques of aortas obtained
from autopsy cases, kind gifts from Dr. Numano of
.Tokyo Medical and Dental University, Tokyo, Japan
over a period of two months. Spleen cells from the
immunized mice were fused with P3rU1 murine
myeloma cells. Culture supernatants of the hy-
bridoma were screened by enzyme-linked immuno-
 .sorbent assay ELISA using OxLDL and native LDL
 .as antigen 1 mg proteinrwell . The isotype of DLH2
 . Fig. 3. Immunoblot analyses of MDA-LDL and MDA-HDL with DLH2. A LDL and MDA-LDL 10 mg for lanes 1–6, 20 mg for lane 7,
.and 30 mg for lane 8 were analyzed by non-reducing SDS-PAGE on a 3–10% gradient gel. Gel was stained with Coomassie brilliant
 .  .  .blue lanes 1 and 2 . Nitrocellulose membranes were treated with anti-human apoB Ab lanes 3 and 4 , DLH2 lanes 5 and 6 or
 .non-immune IgM lanes 7 and 8 , and positive bands were visualized by BCIP-NBT method. Lanes 1, 3, 5 and 7; native LDL, lanes 2, 4,
 .  .6 and 8; MDA-HDL. B HDL and MDA-HDL 20 mg were analyzed by non-reducing SDS-PAGE on a 4–15% gradient gel. Gel was
 .  .  .stained with Coomassie brilliant blue lanes 1 and 2 . Immunoblot analysis with DLH2 lanes 3 and 4 or nonimmune IgM lanes 5 and 6
w125 xwas visualized using I - protein A. Lanes 1, 3, and 5; native HDL, lanes 2, 4 and 6; MDA-HDL.
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was IgM with k-light chain determined using Mouse
 .typer kit Bio-Rad . Ascites fluids were obtained by
injecting hybridomas into mice previously primed
with pristane. The mAb was partially purified from
the ascites fluid by ammonium sulfate precipitation
followed by gel filtration column chromatography on
 .Toyopearl HW-65 Tosoh, Tokyo, Japan .
2.3. ELISA
 .Antigens suspended in PBS 1 mgr100 ml were
placed in wells of a 96-well microtiter plate and
incubated for 18 h at 48C. After removing the antigen
fluid, the wells were blocked with Tris-buffered saline
 .  .TBS containing 2% skim milk TBS-skim milk for
2 h at room temperature. After washing the wells
three times with TBS containing 0.05% Tween 20,
 .DLH2 1:2000 diluted in PBS was reacted for 2 h at
room temperature, followed by an alkaline phos-
 .  .phatase ALP conjugated goat anti-mouse Ig GqM
 .  .antibody Ab Tago, Burlingame, CA, U.S.A.
 .1:5000 diluted in TBS-skim milk for 2 h at room
temperature. Finally, the remaining ALP activity was
determined using p-nitrophenylphosphate as sub-
strate. The results were read spectrophotometrically
as optical density on an ELISA plate reader Bio-Rad,
.model 550 with the filter at 405 nm.
2.4. Immunoblot analysis
 .  .LDL 10 mg and HDL 20 mg treated with or
without MDA were run through 4–15% gradient
polyacrylamide gel containing 0.1% SDS. After elec-
trotransfer, the nitrocellulose membranes were incu-
bated with either 30 mgrml DLH2 or murine IgM, or
 .sheep Ab to human apoB Binding Site, 1r1000 .
After incubating with second Abs rabbit anti-mouse
 .Ig Gq M Ab, ALP-conjugated goat anti-mouse
 .Ig GqM Ab, or ALP-conjugated donkey anti-sheep
.IgG Ab , the positive bands were visualized either by
incubating with coloring reagent containing 5-bromo-
 .4-chloroindoryl phosphate BCIP and nitro blue te-
 .trazolium NBT according to the method of Blake et
w x w125 xal. 24 or by incubating with 0.1 mCirml of I -
labeled protein A for 30 min followed by an auto-
w xradiogram taken by the method of Small et al. 25 .
2.5. Induction of li˝er fibrosis in rats
 .Male Wistar rats 140–150 g were pair-fed ad
libitum for 12 weeks with a nutritionally adequate
liquid high fat diet containing ethanol 36% of the
.total caloric intake or isocaloric carbohydrate with or
 . w xwithout dietary carbonyl iron 0.5% wrv 26 . The
intake volumes the rats pair-fed isocalorically were
70–150 mlrday. Dietary carbonyl iron FERRO-
.NYL was purchased from ISP Chemicals, Tokyo,
Japan. At the end of the experiments, animals were
sacrificed and immunohistochemical analysis of the
livers was carried out. All animals were humanely
treated according to NIH guide for the care and use
of laboratory animals.
2.6. Immunohistochemical analysis
Serial sections of human abdominal aortic tissue
and rat liver were provided for indirect immunohisto-
 .chemical staining. Briefly, acetone-treated 10 min
thin sections were washed in PBS with agitation, and
then incubated with PBS containing 5% bovine serum
 .albumin BSA for 10 min. The first Abs used were
 .DLH2, HAM56 Dako which recognizes human
 .macrophages, anti-human apoB Chemicon , and
 .Mar1 Seikagaku, Japan which recognizes rat
w xmacrophages and Kupffer cells 27 . The sections
were incubated with the diluted first Abs overnight at
48C. Negative control experiments were carried out
either by using non-immune murine IgM Zymed
.Lab or omitting first Ab. After agitation-washing
with PBS, the sections were incubated with ALP-con-
jugated second Abs against mouse or sheep immuno-
 .globulins Dako for 30 min followed by incubation
with ALP-conjugated anti-ALP Ab. Sections were
then washed with PBS and stained with 0.2 M Tris–
 .HCl buffer pH 8.2 containing 0.01% new fucshin
 .Merck , 0.01% NaNO , 10 mg naphtol AS-BI phos-2
 .phate Sigma , 0.1 ml N, N-dimethyl formamide
 .  .Wako, Osaka and 10 mM levamisol Sigma . Sec-
tions were then fixed with 10% formalin, and
counter-stained with hematoxylin.
2.7. Other analytical methods
Protein concentration was measured by the bicin-
 . w xchoninic acid BCA method 28 . Free amino groups
w xwere measured using fluorescamine as a probe 29 .
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3. Results
3.1. Reacti˝ity of DLH2 to chemically modified LDLs
The reactivity of mAb DLH2, which was raised
using homogenate of human atheroma as immuno-
gen, to variously modified and untreated LDLs was
tested. In the ELISA assay, 1 mg each of these sam-
ples was precoated onto plastic ELISA plates to test
the reactivity with the mAb. DLH2 reacted to MDA-
LDL and GA-LDL effectively, while native LDL was
 .inert Fig. 1A . It reacted little to OxLDL under this
experimental condition, although a significant reactiv-
ity was observed at a higher concentration of DLH2
 .1r500 dilution . The reactivity of DLH2 to OxLDL
did not change by prolonged incubation of LDL with
 .CuSO up to 24 h data not shown . When LDL was4
treated with lower concentrations of MDA or GA, the
antigenicity of GA-LDL or MDA-LDL reduced sig-
nificantly and it was almost diminished by reducing
the concentration of the reagents added to LDL down
to 0.1 mM. The loss of free amino group was mini-
mal in LDLs treated with 0.1 mM of MDA or GA
 .Fig. 1B . The mAb, however, did not react to LDL
treated with HNE or 2,4-hexadienal, even when
10 mM of the reagents were used. The HNE- and
2,4-hexadienal-treated LDL preparations lost more
amino groups than MDA-LDL. Chemical modifica-
tion of LDL did not affect the amounts adsorbed onto
the plastic surface of microtiter wells in this ELISA
 .assay data not shown . In a separate experiment,
DLH2 showed no reactivity to glycated LDL re-
.  .maining free amino group 51% data not shown .
These results suggest that modification of LDL by
divalent reagents could be antigenic, but the modifi-
cation of LDL with aldehyde reagents is not enough.
3.2. Reacti˝ity of DLH2 to cross linked proteins
The specificity of the mAb against apoB moiety of
modified LDL was investigated by treatment of vari-
ous proteins with MDA. As shown in Fig. 2, HDL,
BSA and bovine hemoglobin as well as LDL were
positive after the treatment. MDA-LDL showed the
strongest reactivity, although the loss of free amino
groups in the MDA-treated LDL proteins was slightly
less than the others. Other proteins tested, such as
lysozyme, ovalbumin, and collagen were not reactive
with DLH2 by the ELISA assay when they were
 .treated with MDA data not shown . Poor solubility
 .modified collagen and ovalbumin , or poor reactivity
 .to the aldehyde cross linkers lysozyme might cause
the low reactivity. It seems likely that DLH2 is not
specific for apoB but requires certain physico-
chemical properties of proteins to be modified.
To further investigate the reactivity of DLH2 to
cross linked proteins, immunoblot analyses of MDA-
 .LDL and MDA-HDL were carried out Fig. 3 . Treat-
ment of LDL with MDA reduced its electromobility
suggesting the formation of cross linked apoB pro-
 . .teins Fig. 3B , lanes 2 and 4 . DLH2 detected the
 .MDA-LDL 10 mg whilst non-immune murine IgM
failed to detect MDA-LDL even though 30 mg of
 .antigen were used Fig. 3A, lanes 6 and 8 . After
treatment of HDL with MDA, a smeared band rang-
ing from 90–140 kDa appeared which corresponds to
 .cross linked proteins Fig. 3B, lane 2 . The smeared
band was positive when the transfer membrane was
 .treated with DLH2 Fig. 3B, lane 4 . This HDL
preparation was not highly purified so that it still
contained small amount of albumin and apoB. How-
ever, it is noteworthy that the apolipoprotein AI and
albumin remained at the original sizes in the MDA-
HDL preparation were not reactive to DLH2, al-
though they were possibly modified by MDA. A
small band at 500 kDa was also detected by DLH2.
Since the 500 kDa band was slightly larger than apoB
present in the HDL preparation, it may be apoB cross
linked with smaller proteins. A weak band at 240 kDa
was observed on the native HDL, but this band was
also detected with non-immune IgM Fig. 3B, lanes 3
.and 5 . Proteolytic treatment of MDA-LDL or GA-
LDL with trypsin or V8 protease abolished their
 .reactivity to DLH2 data not shown . These results
suggest that DLH2 recognizes cross linked proteins,
but it is not specific for modified apoB.
3.3. Distribution of DLH2 antigen in human
atheromatous lesions
Surgical specimens of aorta were freshly obtained
from patients 67 year old, female, and 60 year old,
.male receiving an aneurysm resection of abdominal
aorta. Serial thin sections of the aortic tissue were
subjected to immunohistochemical analysis to deter-
mine the localization of DLH2 antigens in athero-
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Fig. 4.
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Fig. 4. Immunohistochemical detection of DLH2 antigen in hu-
man atherosclerotic lesion in a patient with abdominal aneurysm
 .67 year old, female . Serial sections of atheromatous lesion in
 .  .the aorta were stained with Oil Red-O A , anti-human apoB B ,
 .  .  . HAM56 C , DLH2 D , or without first Ab E magnification:
.=50 . Large amounts of Oil Red-O positive lipids and apoB
 .were deposited in necrotic core upper part . Many infiltrating
macrophages were observed at the edge of the core. DLH2
antigen was primarily detected in the foamy macrophages, while
apoB was detected diffusely in collagenous matrix but not in the
cells.
sclerotic lesions. DLH2 was found in necrotic core
 .Fig. 4D , where HAM56 positive materials colocal-
 .  .ized Fig. 4C . While apoB Fig. 4B and neutral
 .lipids Fig. 4A were diffusely accumulated in
necrotic lesion. DLH2 antigen was found intra-
cellularly in neutral lipid-laden foam cells Fig. 4A,
.C and D . ApoB, however, was found to be deposited
 .in collagenous matrix but not in the cells Fig. 4B .
Fig. 5 shows a vaso vasorum in atheromatous lesion.
This small artery shows mild fibromascular intimal
thickening. Although no lipid accumulation was de-
 .tected in this artery Fig. 5A , both DLH2 antigen
and apoB were clearly observed in the endothelial
 .layer Fig. 5B and C . No staining was observed
when either the first Ab was omitted Fig. 4E and
Fig. 5D or non-immune murine IgM was used data
.not shown . The staining was abolished by addition
of MDA-LDL to the DLH2 antigen solution incubat-
ing with the histochemical specimens, whilst either
native LDL or OxLDL did not reduce the staining
 .data not shown . These results indicate that the
 .presence of DLH2 antigen s in human athero-
sclerotic lesions. Furthermore it is interesting to note
that the localization of DLH2 does not correspond to
that of apoB.
3.4. Appearance of the antigen in Kupffer cells in
pre-hepatic fibrosis
It has been known that lipid peroxidation is in-
volved in progressive liver injury from fatty liver to
cirrhosis. We used an established animal model in
which hepatic fibrosis is induced by feeding a high
w xfat diet containing alcohol and carbonyl iron 22 .
The liver of rats fed alcohol together with iron in the
present study, showed a pre-fibrosis state which is
characterized by normohepatic tissue with mild bile
retention. DLH2 antigen clearly accumulated in an
 .enlarged cellular cytoplasm Fig. 6B . The DLH2
positive cells, which located near the portal areas of
the liver in rats treated with alcohol and iron, were
identified as Kupffer cells by Mar1 antibody data
.not shown . DLH2 antigen in the rats treated with
alcohol alone had a scattered distribution in Kupffer
cells and the size of the positive cells was markedly
smaller than that in the rats treated with alcohol and
 .iron Fig. 6A . Almost no cell was stained in the liver
of control rats. When an anti-human apoB Ab was
used for reference, apoB seemed to be localized
along the sinusoid, but not in the Kupffer cells where
 .DLH2 antigen was accumulated data not shown .
4. Discussion
The new mAb DLH2 obtained in this study has
appeared to react strongly to cross linked proteins.
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Fig. 5. Immunohistochemical detection of DLH2 antigen in a small artery with mild intimal thickening in a patient with abdominal
 .  .  .  .aneurysm 60 year old, male . Serial sections of the artery were stained with Oil Red-O A , DLH2 B , anti-human apoB C , or without
 .  .first Ab D magnification: =50 . Although no lipid was deposited in the artery, DLH2 antigen was detected in endothelial layer, where
apoB was also deposited.
Firstly, DLH2 was highly reactive to MDA-LDL and
GA-LDL while HNE-LDL and 2,4-hexadienal-LDL
failed. Secondly, cross linked products formed in
MDA-LDL and MDA-HDL preparations were de-
tected by immunoblot analysis. A unique feature of
this antibody is to recognize cross linked proteins, not
merely MDA adducts. However, this mAb is not
specific for apoB protein, therefore certain protein
structure or peptide motif is likely to be an additional
important factor in antigen recognition.
Using this mAb we demonstrated the presence of
cross linked proteins in human atheroma. The distri-
bution of DLH2 antigen corresponded well to
macrophage-derived foam cells. It should be noted
that the distribution of DLH2 antigen did not corre-
spond to that of apoB protein in atheromatous lesions
and in fibrotic liver. One possibility is that the anti-
 .gen s in the lesions could be derived from certain
materials other than LDL. Accumulation of MDA-
modified collagen in the glomeruli in rats with
w xnephrotic syndrome was reported 12 . Another possi-
bility is that lysosomal degradation of modified LDL
in macrophages decreases the immunoreactivity of
apoB moiety of the modified LDL. Lysosomal degra-
w125 xdation of I -labeled OxLDL has been shown to be
less efficient than that of native LDL, and the degra-
dation of modified LDLs was suggested to depend on
w xcross linking and types of reagents 30,31 .
Several other groups have obtained anti-MDA-
w xlysine mAbs 18,19 . Antigens detected by the anti-
MDA-lysine mAbs showed cell associated as well as
extracellular distributions in atherosclerotic lesions of
WHHL rabbit and balloon-injured rabbit aortas
w x w x18,19 . Palinski et al. 32 reported that antigens
detected by anti-MDA-lysine and anti-HNE antibod-
ies were observed in macrophages in early lesions,
but they were also present in extracellular spaces in
advanced lesions of atheromatous aorta in apolipo-
protein E knockout mice. These results together with
ours suggest that the possible importance of protein
modification with MDA in atherosclerosis, and that a
part of MDA-modified proteins previously detected
in pathological conditions may be cross linked pro-
teins. There are some difference in the antigen distri-
butions detected by these antibodies in atherosclerotic
lesions. DLH2 is likely to have different determinants
of antigen recognition from the anti-MDA-lysine
mAbs, since DLH2 is not specific for MDA adducts
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Fig. 6. Immunohistochemical detection of DLH2 antigens in rats
treated with alcohol and carbonyl iron. The liver in rats fed with
 .  .alcohol alone A or alcohol and carbonyl iron B was stained
 .with DLH2 magnification: =25 . DLH2 antigen was markedly
accumulated in an enlarged cellular cytoplasm of Kupffer cells in
rats fed with alcohol and iron, while rats treated with alcohol
alone accumulated DLH2 antigen to a less extent.
but is reactive to modified proteins cross linked by
divalent aldehydes including MDA.
Our present study also demonstrated that there is
massive accumulation of DLH2 antigen in Kupffer
cells of rats treated with alcohol and iron. Involve-
ment of lipid peroxidation in this alcoholic liver
disease model has been shown by increased levels of
thiobarbituric acid reactive substances and HNE
w x5,13 . Early hepatic damage induced by alcohol and
iron may induce oxidative modification of various
components in addition to LDL. The possibility that
the proteins are modified in extra hepatic tissues
cannot be ruled out, since DLH2 antigen did not
accumulate significantly in liver parenchyme, includ-
ing hepatocytes. Oxidatively modified LDL is effec-
tively incorporated in Kupffer cells presumably to
remove it from blood stream, and Kupffer cells have
been shown to incorporate modified LDLs when
w xinjected intravenously 33 . Cross linked proteins may
also be effectively incorporated by Kupffer cells.
Polyclonal antisera raised against MDA-LDL and
HNE-LDL, however, stained liver parenchyme of rats
treated with alcohol and iron in our previous study
w x5 . These results suggest the possibility that struc-
turally different modified proteins could have
metabolic differences as well.
DLH2 antigen in human atheromatous aorta was
localized to foam cells. The apparent distribution of
DLH2 antigen in pre-fibrotic rat liver seemed similar
to that of aorta, since it was found primarily in
macrophages or Kupffer cells. On the other hand,
DLH2 antigen was also detected in endothelial layer
of small artery which did not have atherosclerosis.
The antigenic materials may localize differently in
early stages of lesion formation and in advanced
necrotic lesions. Macrophage-like cells in a variety of
tissues including Kupffer cells express trimeric scav-
w xenger receptor, SR-AI and II 34 , which may be
responsible for the accumulation of DLH2 antigen in
atheromatous aorta and in prefibrotic liver. However,
there are more than one, possibly several different
types of receptors for modified LDL on macrophages
w x33–37 . Although all of those are capable of incor-
porating OxLDL and various modified proteins, they
may have different specificity for cross linked pro-
teins and different ability to metabolize them.
In conclusion, using a unique mAb we found
cell-associated appearance of cross linked proteins in
damaged tissues in which lipid peroxidation is thought
to be involved. More work is needed to understand
how the DLH2 antigen accumulates in injured tis-
sues. In future studies we intend to further investigate
the metabolism and pathological involvement of ox-
idative modification of LDL by tagging different
parts of those particles with DLH2 together with
other mAbs of the series.
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